RALOXIFENE GxP Raloxifene hydrochloride 60 mg tablets, blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

raloxifene hydrochloride, Quantity: 60 mg

Disponible desde:

MedTAS Pty Ltd

Designación común internacional (DCI):

Raloxifene hydrochloride

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; glycine; colloidal anhydrous silica; polysorbate 80; povidone; titanium dioxide; hypromellose; Carnauba Wax; macrogol 400

Vía de administración:

Oral

Unidades en paquete:

28 tablets

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

Resumen del producto:

Visual Identification: White to off-white, oval, biconvex, film coated tablets with 'C' on one side and '12' on other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Estado de Autorización:

Licence status A

Fecha de autorización:

2014-01-14